Publication | Open Access

Novel Interaction Mechanism of a Domain Antibody-based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency than Ranibizumab and Bevacizumab and Improved Capacity over Aflibercept

InflammationNovel Interaction MechanismAngiogenesisMedicineVascular Endothelial Growth FactorImmunologyEndothelial DysfunctionDomain Antibody-based InhibitorVascular BiologyNeovascularizationImmunotherapyPharmacologyGreater Potency